Compare Stocks: SLS, PCVX, IBRX, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.64 +4.4%	$7.66	$1.95 ▼ $12.43	$8.10B	0.03	9.41 million shs	9.38 million shs
PCVX Vaxcyte	$58.07 -1.4%	$53.85	$29.29 ▼ $65.00	$8.39B	1.23	972,607 shs	1.30 million shs
RYTM Rhythm Pharmaceuticals	$115.63 +3.1%	$102.51	$74.50 ▼ $122.20	$7.92B	1.92	700,335 shs	672,761 shs
SLS SELLAS Life Sciences Group	$12.01 +2.6%	$10.92	$1.39 ▼ $15.88	$2.36B	2.48	6.47 million shs	5.09 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+6.56%	-13.87%	-10.22%	+221.01%
PCVX Vaxcyte	0.00%	+7.38%	-2.94%	+9.55%	+75.97%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+0.13%	+22.79%	+28.46%
SLS SELLAS Life Sciences Group	0.00%	+19.98%	-11.10%	+139.72%	+655.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.64 +4.4%	$7.66	$1.95 ▼ $12.43	$8.10B	0.03	9.41 million shs	9.38 million shs
PCVX Vaxcyte	$58.07 -1.4%	$53.85	$29.29 ▼ $65.00	$8.39B	1.23	972,607 shs	1.30 million shs
RYTM Rhythm Pharmaceuticals	$115.63 +3.1%	$102.51	$74.50 ▼ $122.20	$7.92B	1.92	700,335 shs	672,761 shs
SLS SELLAS Life Sciences Group	$12.01 +2.6%	$10.92	$1.39 ▼ $15.88	$2.36B	2.48	6.47 million shs	5.09 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+6.56%	-13.87%	-10.22%	+221.01%
PCVX Vaxcyte	0.00%	+7.38%	-2.94%	+9.55%	+75.97%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+0.13%	+22.79%	+28.46%
SLS SELLAS Life Sciences Group	0.00%	+19.98%	-11.10%	+139.72%	+655.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	85.86% Upside
PCVX Vaxcyte	2.38	Hold	$86.00	48.10% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	23.18% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-16.74% Downside

Current Analyst Ratings Breakdown

Latest SLS, PCVX, IBRX, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$142.00 ➝ $143.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $155.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$155.00 ➝ $160.00
7/27/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
7/17/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SLS SELLAS Life Sciences Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	71.47	N/A	N/A	($0.51) per share	-14.98
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	41.76	N/A	N/A	$2.08 per share	55.59
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	N/A
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	N/A
SLS SELLAS Life Sciences Group	-$26.86M	-$0.23	N/A	N/A	N/A	N/A	-47.12%	-42.63%	8/11/2026 (Estimated)

Latest SLS, PCVX, IBRX, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
5/12/2026	Q1 2026	SLS SELLAS Life Sciences Group	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	5.72	5.70
PCVX Vaxcyte	N/A	5.72	5.72
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SLS SELLAS Life Sciences Group	N/A	17.22	17.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
PCVX Vaxcyte	96.78%
RYTM Rhythm Pharmaceuticals	N/A
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
PCVX Vaxcyte	3.30%
RYTM Rhythm Pharmaceuticals	5.90%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable
PCVX Vaxcyte	160	144.40 million	139.63 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SLS SELLAS Life Sciences Group	10	196.63 million	194.08 million	Not Optionable

SLS, PCVX, IBRX, and RYTM Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher - Time to Buy?

August 3, 2026 | marketbeat.com

SLS stock eyes green start to August after nearly $6M in fresh institutional buying: Retail stays bearish

August 3, 2026 | msn.com

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

August 2, 2026 | seekingalpha.com

SELLAS Life Sciences Group (SLS) Projected to Announce Earnings on Thursday

August 1, 2026 | americanbankingnews.com

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday

August 1, 2026 | marketbeat.com

SLS stock in spotlight after Vanguard Capital discloses 5.19% stake – retail calls it 'huge vote of conviction' as AML trial readout nears

July 31, 2026 | msn.com

SLS stock turns green after 3-day rout: Five investors add shares as key AML trial nears final trigger

July 31, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 12.5% - Should You Sell?

July 28, 2026 | marketbeat.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

July 28, 2026 | marketbeat.com

SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout

July 28, 2026 | finance.yahoo.com

3D prevails in arbitration against Sellas, awarded $1M in costs

July 27, 2026 | msn.com

SLS stock climbs premarket: Here’s what smart money is doing as Sellas nears critical phase 3 AML readout

July 27, 2026 | msn.com

Sellas CEO Angelos Stergiou says '100% certain' AI can be used to beat cancer

July 24, 2026 | msn.com

SLS stock rises overnight: Retail traders call new AML survival data 'huge' ahead of CEO’s Fox appearance

July 24, 2026 | msn.com

SLS stock July rout deepens: 'Pharma Bro' Martin Shkreli questions timing of AML trial, says data may wait until Christmas

July 23, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.3% - What's Next?

July 22, 2026 | marketbeat.com

SLS stock tracks worst month since March: Investor slashes stake by over 30% as quiet period begins ahead of AML readout

July 22, 2026 | msn.com

SLS stock rises overnight: Retail thinks CEO just dropped buyout clues ahead of Fox appearance

July 21, 2026 | msn.com

SLS stock hits July low as AML readout nears — retail bulls see 'stellar' hint in CEO's Fox appearance next week

July 18, 2026 | msn.com

SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns

July 18, 2026 | finance.yahoo.com

SELLAS Life Sciences rebounds 12% as investors continue to wait for key data

July 18, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PCVX, IBRX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

$7.64 +0.32 (+4.37%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.59 -0.05 (-0.68%)

As of 08/7/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Vaxcyte NASDAQ:PCVX

$58.07 -0.82 (-1.39%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$58.06 -0.01 (-0.01%)

As of 08/7/2026 07:34 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$115.63 +3.53 (+3.15%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$117.50 +1.87 (+1.62%)

As of 08/7/2026 07:34 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

SELLAS Life Sciences Group NASDAQ:SLS

$12.01 +0.31 (+2.65%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.07 +0.06 (+0.51%)

As of 08/7/2026 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, PCVX, IBRX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, PCVX, IBRX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, PCVX, IBRX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PCVX, IBRX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

Vaxcyte NASDAQ:PCVX

Rhythm Pharmaceuticals NASDAQ:RYTM

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, PCVX, IBRX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, PCVX, IBRX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, PCVX, IBRX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, PCVX, IBRX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

Vaxcyte NASDAQ:PCVX

Rhythm Pharmaceuticals NASDAQ:RYTM

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools